Taking informed consent seriously in global HIV vaccine research

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 2, 2003, Pages 117-123

  Mariner, Wendy K ^a  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DECISION MAKING; DEVELOPING COUNTRY; DRUG EFFICACY; EDITORIAL; ETHICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INFORMED CONSENT; LEGAL ASPECT; METHODOLOGY; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; UNITED STATES;

EID: 0037319892     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200302010-00001     Document Type: Editorial

References (98)

1. French HW. AIDS research in Africa: juggling risks and hopes. New York Times, Oct. 9, 1997:A1.
2. Office of Inspector General, Department of Health and Human Services. Recruiting Human Subjects: Sample Guidelines for Practice. Washington DC, June 2000 (OEI-01-97-00196).
3. Shalala D. Protecting research subjects: what must be done? N Engl J Med 2000;343:808-810.
4. Federman DD, Hanna KE, Rodriguez LL, eds. Committee on Assessing the System for Protecting Human Research Participants, Institute of Medicine. Responsible Research: A Systems Approach to Protecting Research Participants. Washington DC: National Academies Press, 2002.
5. Marshall E. Clinical research: Fred Hutchinson Center under fire. Science 2001;292:25.
6. Marshall E. Clinical research: shutdown at Hopkins sparks a debate. Science 2001;293:587-589.
7. Verheggen FWSM, van Wijmen FCB. Informed consent in clinical trials. Health Policy 1998;36:131-153.
8. Edwards SJL, Lilford RJ, Thornton J, et al. Informed consent for clinical trials: in search of the "best" method. Soc Sci Med 1998;47:1825-1840.
9. Sugarman J, McCrory DC, Powell D, et al. Empirical research on informed consent. Hastings Center Rep Jan 1999;29(suppl):S1-S42.
10. Dunn LB, Jeste DV. Enhancing informed consent for research and treatment. Neuropsychopharmacology 2001;24:595-607.
11. Silva MD, Sorrell JM. Enhancing comprehension of information for informed consent: a review of empirical research. IRB 1988;10:1-6.
12. Coletti AS, Heagerty P, Sheon AR, et al. Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr 2003;32:161-169.
13. Cohen J. Shots in the Dark: The Wayward Search for an AIDS Vaccine. New York: WW Norton & Company; 2001;10.
14. National Bioethics Advisory Commission. Ethical And Policy Issues In Research Involving Human Participants. Bethesda, MD: National Bioethics Advisory Commission; Aug. 2001.
15. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Making Health Care Decisions: Volume One: Report. Washington, DC: U.S. Government Printing Office; 1982.
16. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines For The Protection Of Human Subjects Of Research. Washington, DC: U.S. Government Printing Office; 1978.
17. Annas GJ, Glantz LH, Katz B. Informed Consent To Human Experimentation: The Subject's Dilemma. Cambridge, MA: Ballinger Books; 1977.
18. Katz J. Experimentation in Human Beings. New York: Russell Sage Foundation, 1972.
19. Nuremberg Code. In: Trials of War Criminals Before The Nuremberg Military Tribunals under Control Council Law. Washington, DC: U.S. Government Printing Office, 1949, No. 10, vol. II, 181-182.
20. Annas GJ, Grodin MA, eds. The Nazi Doctors and the Nuremberg Code. New York: Oxford University Press; 1992.
21. Office of Science and Technology Policy. Federal Policy for the Protection of Human Subjects. Federal Register 1991;56:28002-28032 [The "Common Rule"].
22. U.S. Department of Health and Human Services. Protection of Human Subjects. Code of Federal Regulations, Title 45, Part 46.
23. Council for International Organizations of Medical Sciences, World Health Organization. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva: CIOMS; 1993.
24. Mann J, Gruskin S, Grodin MA, Annas GJ, eds. Health and Human Rights: A Reader. New York: Routledge; 1999.
25. World Medical Association. Declaration of Helsinki. In: Annas GJ, Grodin MA, eds. The Nazi Doctors and the Nuremberg Code. New York: Oxford University Press; 1992.
26. National Bioethics Advisory Commission. Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries, vol. I: Report and Recommendations. Bethesda, Md.: National Bioethics Advisory Commission; April 2001.
27. Katz J. The Silent World of Doctor and Patient. New York: Free Press; 1984.
28. Faden RR, Beauchamp TL. A History and Theory of Informed Consent. New York: Oxford University Press; 1986.
29. WK Mariner. Informed consent in the post-modern era. Law & Social Inquiry 1988;13:385-406.
30. Doyal L, Tobias JS, eds. Informed Consent in Medical Research. London: BMJ Publishing Group; 2001.
31. Mariner WK. The common law of human experimentation. In: Murray TH, Mehlman MJ, eds. Encyclopedia Of Ethical, Legal, and Policy Issues in Biotechnology. New York: John Wiley & Sons, Inc.; 2000.
32. Tuskegee Syphilis Study Ad hoc Advisory Panel. Final Report. Washington, DC: U.S. Department of Health, Education and Welfare; 1973.
33. Office of Inspector General, Department of Health and Human Services. Globalization of Clinical Trials: A Growing Challenge in Protecting Human Subjects. Washington, DC, Sept. 2001 (OEI-01-00-00190).
34. LaFraniere S, Flaherty MP, Stephens J. The dilemma: submit or suffer: 'uninformed consent' is rising ethic of the drug test boom. The Washington Post, Dec. 19, 2000:A1.
35. Flaherty MP, Nelson D, Stephens J. Testing tidal wave hits overseas: on distant shores, drug firms avoid delays-and scrutiny. The Washington Post, Dec. 18, 2000:A1.
36. Office of Inspector General, Department of Health and Human Services. Recruiting Human Subjects: Pressures in Industry Sponsored Research. Washington, DC, June 2000 (OEI-01-97-00195).
37. Stolberg SG. Civilians are reluctant to join U.S. test of anthrax vaccine. New York Times, Jan. 8, 2002:A13.
38. Corbie-Smith G, Thomas SB, St. George DMM. Distrust, race, and research. Arch Intern Med 2002;162:2458-2463.
39. Sengupta S, Strauss RP, DeVellis R, et al. Factors affecting African-American participation in AIDS research. J Acquir Immune Defic Syndr 2000;24:275-284.
40. Grady C. The Search for an AIDS Vaccine: Ethical Issues in the Development and Testing of a Preventive HIV Vaccine. Bloomington, IN: Indiana University Press; 1995.
41. U.S. Congress, Office of Technology Assessment. Adverse Reactions to HIV Vaccines: Medical, Ethical and Legal Issues. OTABP-H-163. Washington DC: U.S. Government Printing Office; 1995.
42. AIDS Action Foundation. HIV Preventive Vaccines: Social, Ethical, and Political Considerations for Domestic Efficacy Trials. Washington DC; 1994.
43. Hodel D. HIV Preventive vaccine efficacy trials in the US: overview of target communities' concerns. AIDS Res Human Retroviruses 1994(Suppl 2):S255-56.
44. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:266-271.
45. Mariner WK. The ethical conduct of clinical trials of HIV vaccines, evaluation research 1990; 14:538-564. Reprinted in Schuklenk U, ed. AIDS: Society, Ethics and Law. Hants, England: Dartmouth Publishing Co.;2001:317-343.
46. Mariner WK. The ethical conduct of clinical trials of HIV vaccines, evaluation research 1990; 14:538-564. Reprinted in Schuklenk U, ed. AIDS: Society, Ethics and Law. Hants, England: Dartmouth Publishing Co.;2001:317-343.
47. Grinstead OA. Social and behavioral issues in phase III HIV preventive vaccine trials. AIDS 1995(9 Supp A):S245-250.
48. Kahn JP, Mastroianni AC. Moving from compliance to conscience: why we can and should improve on the ethics of clinical research. Arch Intern Med 2001;161:925-928.
49. Angell M. Investigators' responsibilities for human subjects in developing countries. N Engl J Med 2000;342:967-969.
50. Turner CF, Sheon AR. Behavioral studies relevant to vaccine trial preparation: an introduction. AIDS Res Human Retroviruses 1994; 10(Suppl):273-276.
51. Chesney MA, Lurie P, Coates TJ. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:30-35.
52. King NMP. Experimental treatment: oxymoron or aspiration? Hastings Center Report 1995;25:6-15.
53. Applebaum PS, Roth LH, Lidz CW, et al False hopes and best data: consent to research and the therapeutic misconception. Hastings Center Report 1987;17:20-24.
54. Preziosi M-P, Yam A, Ndiaye M et al. Practical experiences in obtaining consent for a clinical trial in rural Africa. N Engl J Med 1997;336:370-373.
55. Stone VE, Mauch MY, Steger K, et al. Race, gender, drug use, and participation In AIDS clinical trials: lessons from a municipal hospital cohort. J Gen Intern Med 1997;12:150-157.
56. Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? Am J Epidemiol 2001;153:619-627.
57. Harrison K, Vlahov D, Jones K, et al. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:386-390.
58. Lynoe N, Hyder Z, Chowdhury M, et al. Obtaining informed consent in Bangladesh. N Engl J Med 2001;344:460-461.
59. Ramjee G, Morar NS, Alary M, et al. Challenges in the conduct of vaginal microbicide effectiveness trials in the developing world. AIDS 2000;14:2553-2557.
60. Leach A, Hilton S, Greenwood BM, et al. An evaluation of the informed consent procedure used during a trial of a haemophilus influenzae type B conjugate vaccine undertaken in the Gambia, West Africa. Soc Sci Med 1999;48:139-148.
61. Limpakarnjanarat K, Chuaachoowong R, Bhadrakom C, et al. Informed consent for a clinical trial in Thailand. N Engl J Med 1998;339:1331-1332.
62. Langan M, Collins C. Paving the Road to an HIV Vaccine: Employing Tools of Public Policy to Overcome Scientific, Economic, Social and Ethical Obstacles. San Francisco, CA: Center for AIDS Prevention Studies [monograph]; 1998.
63. Belshe RB, Stevens C, Buchbinder S, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp 120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001;183:1343-1352.
64. Office of Inspector General, U.S. Department of Health and Human Services. Institutional Review Boards: A Time for Reform. Washington DC: Dept. of Health & Human Services, June 1998 (OEI-01-97-00193).
65. U.S. General Accounting Office. Scientific Research: Continued Vigilance Critical to Protecting Human Research Subjects. Washington, DC: USGAO, 1996.
66. Lavori PW, Sugarman J, Hays MT, et al. Improving informed consent in clinical trials: a duty to experiment. Controlled Clinical Trials 1999;20:187-193.
67. Fitzgerald DW, Marotte C, Verdier RI, et al. Comprehension during informed consent in a less-developed country. Lancet 2002;360:1301-1302.
68. Lynoe N, Sandlund M, Dahlqvist G, et al. Informed consent: study of the quality of information given to participants in a clinical trial. BMJ 1991;303:610-613.
69. Corbett F, Oldham J, Lilford RJ. Offering patients entry in clinical trials: the views of prospective participants. J Medical Ethics 1996;22:227-231.
70. Annas GJ. Reforming informed consent to genetic research. JAMA 2001;286:2326-2328.
71. Guenter D, Esparza J, Macklin R. Ethical considerations in international HIV vaccine trials: summary of a consultative process conducted by the Joint United Nations Programme on HIV/AIDS (UNAIDS). J Medical Ethics 2000;26:37-43.
72. Faden R, Kass N. HIV research, ethics, and the developing world. Am J Public Health 1998;88:548-550.
73. Porter JP. Informed consent issues in international research concerns. Cambridge Quarterly of Healthcare Ethics 1996;5:237-243.
74. Lurie P, Bishaw M, Chesney M, et al. Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries. JAMA 1994;271:295-301.
75. McGrath J, George K, Svilar IE, et al. Knowledge about vaccine trials and willingness to participate in an HIV/AIDS vaccine study in the Ugandan military. J Acquir Immune Defic Syndr 2001;27:381-388.
76. Leach A, Hilton S, Greenwood BM, et al. An evaluation of the informed consent procedure used during a trial of a haemophilus influenzae type B conjugate vaccine undertaken in the Gambia, West Africa. Soc Sci Med 1999;48:139-148.
77. Queiroz da Fonseca Jr. O, Lie RK. Informed consent to preventive AIDS vaccine trials in Brazil: a pilot study. AIDS Public Policy J 1995;10:22-26.
78. McGrath JW, Mafigiri D, Kamya M, et al. Developing AIDS vaccine trials educational programs in Uganda. J Acquir Immune Defic Syndr 2001;26:176-181.
79. Temoshok LR. Behavioral research contributions to planning and conducting HIV vaccine efficacy studies. AIDS Res Human Retroviruses 1994;10(Suppl 2):S277-S280.
80. Turner CF, Sheon AR. Behavioral studies relevant to vaccine trial preparation: an introduction. AIDS Res Human Retroviruses 1994;10(Suppl 2):S273-S276.
81. Newton LH. Ethical imperialism and informed consent. IRB 1990;12:10-11.
82. Levine RJ. Informed consent: some challenges to the universal validity of the Western model. Law, Medicine, & Health Care 1991;19:207-213.
83. Angell M. Ethical imperialism? Ethics in international collaborative clinical research. N Engl J Med 1988;319:1081-1083.
84. Barry M. Ethical considerations of human investigation in developing countries: the AIDS dilemma. N Engl J Med 1988;319:1083-1086.
85. Macklin R. Against Relativism: Cultural Diversity and the Search for Ethical Universals in Medicine. New York: Oxford University Press, 1999.
86. Ijsselmuiden C, Faden R. Research and informed consent in Africa: another look. N Engl J Med 1992. Reprinted in Mann et al, eds. Health and Human Rights: A Reader. New York:Rouledge; 1999.
87. Ijsselmuiden C, Faden R. Research and informed consent in Africa: another look. N Engl J Med 1992. Reprinted in Mann et al, eds. Health and Human Rights: A Reader. New York:Rouledge; 1999.
88. Anonymous. Organisation of African Unity adopts resolution on bioethics. Int Dig Health Legislation 1997;48:239-240.
89. Guenter D, Esparza J, Macklin R. Ethical considerations in international HIV vaccine trials: summary of a consultative process conducted by the Joint United Nations Programme on HIV/AIDS (UNAIDS). J Med Ethics 2000;26:37-43.
90. Glantz LH, Annas GJ, Grodin MA, et al. Research in developing countries: taking "benefit" seriously. Hastings Center Report 1998;28:38-42.
91. Mariner WK. Distinguishing "exploitable" from "vulnerable" populations: when consent is not the issue. In: Bankowski Z, Levine RJ, eds. Ethics and Research on Human Subjects: International Guidelines. Geneva, Switzerland: CIOMS;1993:44-55.
92. Angell M. The ethics of clinical research in the third world. N Engl J Med 1997;337:847-49.
93. Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med 1997;337:853-855.
94. Varmus H, Satcher D. Ethical complexities of conducting research in developing countries. N Engl J Med 1997;337:1003-1005.
95. Office of Inspector General, U.S. Department of Health and Human Services. Protecting Human Research Subjects: Status of Recommendations. Washington DC: Dept. of Health & Human Services, April 2000 (OEI-01-97-00197).
96. Research Revitalization Act of 2002, S. 3060, 107th Congress, 2d Session, introduced October 4, 2002.
97. Weiss R, Nelson D. Methods faulted in fatal gene therapy. The Washington Post, Dec. 8. 1999:A1.
98. Fox JL. Gene therapy death prompts broad civil lawsuit. Nature Biotechnology 2000;18:1136.